0.41
0.86%
+0.0035
AIM ImmunoTech Inc stock is currently priced at $0.41, with a 24-hour trading volume of 6,282.
It has seen a +0.86% increased in the last 24 hours and a -6.61% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.4068 pivot point. If it approaches the $0.4385 resistance level, significant changes may occur.
Previous Close:
$0.4065
Open:
$0.41
24h Volume:
6,282
Market Cap:
$20.63M
Revenue:
$193.00K
Net Income/Loss:
$-20.78M
P/E Ratio:
-1.025
EPS:
-0.4
Net Cash Flow:
$-18.14M
1W Performance:
-11.83%
1M Performance:
-6.61%
6M Performance:
-5.75%
1Y Performance:
-17.10%
AIM ImmunoTech Inc Stock (AIM) Company Profile
Name
AIM ImmunoTech Inc
Sector
Industry
Phone
352 448 7797
Address
2117 SW Highway 484, Ocala, FL
AIM ImmunoTech Inc Stock (AIM) Latest News
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
GlobeNewswire Inc.
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
GlobeNewswire Inc.
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
GlobeNewswire Inc.
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
GlobeNewswire Inc.
AIM ImmunoTech 宣布 Ampligen 与 Pembrolizumab 联合用药治疗复发性卵巢癌的研究取得积极顶线、方案计划中期报告数据
GlobeNewswire Inc.
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
GlobeNewswire Inc.
AIM ImmunoTech Inc Stock (AIM) Financials Data
AIM ImmunoTech Inc (AIM) Revenue 2024
AIM reported a revenue (TTM) of $193.00 thousand for the quarter ending September 30, 2023, a +44.03% rise year-over-year.
AIM ImmunoTech Inc (AIM) Net Income 2024
AIM net income (TTM) was -$20.77 million for the quarter ending September 30, 2023, a +0.61% increase year-over-year.
AIM ImmunoTech Inc (AIM) Cash Flow 2024
AIM recorded a free cash flow (TTM) of -$18.14 million for the quarter ending September 30, 2023, a -13.13% decrease year-over-year.
AIM ImmunoTech Inc (AIM) Earnings per Share 2024
AIM earnings per share (TTM) was -$0.43 for the quarter ending September 30, 2023, a 0.00% decline year-over-year.
About AIM ImmunoTech Inc
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd. for the evaluation and discussion of business relationships concerning a COVID-19 therapeutic and vaccine. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
Cap:
|
Volume (24h):